A Phase 2 interventional study of Ponatinib in Myeloid Leukemia, Chronic, Chronic Phase, sponsored by Takeda. Completed at 86 sites in 21 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-03-17.
Sponsored by Takeda · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 339 studies in Leukemia, Myeloid, Chronic-Phase with a site in United States — 12 open to participants now, 27 under way, 2 of them phase 3. Leukemia, Myeloid, Chronic-Phase · United States.
Among the 339 studies in Leukemia, Myeloid, Chronic-Phase with a site in United States, this one is the 15th largest by enrollment of the 255 interventional ones that give a count, is one of 5 that started in 2015, is one of 139 in phase 2, and was the 298th registered.
439 studies on the registry are indexed under Leukemia, Myeloid, Chronic-Phase; 27 are open to participants now.
Browse Leukemia, Myeloid, Chronic-Phase studies →12 of the 339 studies in Leukemia, Myeloid, Chronic-Phase with a site in United States are open now. Recruiting first, the newest first:
Enliven Therapeutics · Sites in United States
Ages 18+
City of Hope Medical Center · Sites in United States
Ages 18–75 · Healthy volunteers
Novartis Pharmaceuticals · Sites in United States
Ages 18–100
Terns, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) · Sites in United States, Australia, France and 6 more countries
Ages 18+
Ascentage Pharma Group Inc. · Sites in United States, Australia, Belgium and 13 more countries
Ages 18+
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 21 Leukemia, Myeloid, Chronic-Phase studies recruiting now, 14 (67%) set no upper age limit and 5 (24%) stop at 75 or younger; 3 take children under 18; 1 takes healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
339 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 91 · Phase 2 166 · Phase 3 40 · Phase 4 3
First in 1988; this study’s year is marked. 5 started in 2015.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 283 is above the median of 43 across 322 interventional studies indexed under Leukemia, Myeloid, Chronic-Phase.
Median enrollment 38 across the 255 interventional studies, 115 across the 28 observational. Of the 293 that completed or were terminated, 86 (29%) have results posted.
This tab as a report to print or save as PDF → With an account.
33 of 339 have an industry lead sponsor. The 10 most frequent:
Takeda is the lead sponsor of 1,026 studies on the registry; 88 are open to participants now.
Of its 178 completed or terminated interventional studies of FDA-regulated products, 155 (87%) have results posted.
Takeda has 3 studies filed under Leukemia, Myeloid, Chronic-Phase — fewer than ten, so there is no comparison to draw.
3 of the studies in Leukemia, Myeloid, Chronic-Phase with a site in United States that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06423911Phase 3Ascentage Pharma Group Inc.Study of Olverembatinib (HQP1351) in Patients With CML-CP | 2027-06-30 |
| NCT05794880Medical College of WisconsinMCW Alpha/Beta T-Cell and B-Cell Depletion With Targeted ATG Dosing | 2027-05 |
| NCT02727803M.D. Anderson Cancer CenterPersonalized NK Cell Therapy in CBT | 2027-05-31 |
Add all 3 to your calendar (.ics) → With an account.
Among the 339 studies in Leukemia, Myeloid, Chronic-Phase with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to characterize the efficacy of ponatinib administered in 3 starting doses (45 mg, 30 mg, and 15 mg daily) in participants with CP-CML who are resistant to prior tyrosine-kinase inhibitor (TKI) therapy or have T315I mutation, as measured by \<=1 % Breakpoint Cluster Region-Abelson Transcript Level using International Scale (BCR-ABL1IS) at 12 months.
The drug being tested in this study is ponatinib. This study will characterize the safety and efficacy of ponatinib over a range of 3 starting doses.
The study will enroll 276 participants in 3 cohorts and each cohort will have 92 participants. All the participants will be randomized to receive once-daily oral administration of 1 of 3 starting doses of ponatinib:
The study is designed to consist of 2 periods: 24-cycle Main treatment period and optional treatment continuation period. Participants will be treated with their randomized dose of study drug in the Main Treatment Period until the occurrence of at least one of the following: absence of CHR by 3 months, absence of MCyR at 12 months, absence of \<=1% BCR-ABL1IS at 12 months, loss of \<=1% BCR-ABL1IS development of intolerance, or completion of all 24 cycles of treatment (whichever occurs first). Following completion of approximately 5 years or following early withdrawal, participants may enter into an optional treatment continuation period.
This multi-center trial will be conducted in the United States, United Kingdom, Republic of Korea, Spain, France, Taiwan, Australia, Canada, Italy, Chile, Japan, Germany, Argentina, Poland, Czech Republic, Denmark, Hong Kong, Portugal, Russia, Singapore, Switzerland, and Sweden. The overall time to participate in this study is approximately 96 months. Participants will make a final visit to the clinic approximately 30 days after the last dose of study treatment.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Have chronic phase-chronic myelogenous leukemia/chronic myeloid leukemia (CP-CML) and have received at least two prior tyrosine kinase inhibitor (TKI) therapies and have demonstrated resistance to treatment OR have documented history of presence of T315I mutation after receiving any number of prior TKI.
o] The diagnosis of chronic myeloid leukemia (CML) will be made using standard hematopathologic and cytogenetic criteria; CP-CML will be defined by all of the following: i \<15% blasts in bone marrow ii \<30% blasts plus promyelocytes in bone marrow iii \<20% basophils in peripheral blood. iv >= 100*10\^9/liter (L) (>=100,000/mm\^3). v No evidence of extramedullary disease except hepatosplenomegaly vi No prior diagnosis of AP-CML, and BP-CML o] Cytogenetic assessment at screening must demonstrate the BCR-ABL1 fusion by presence of the t(9;22) Philadelphia chromosome.
i Variant translocations are only allowed provided they meet inclusion criterion 1d.
o] Resistance to prior TKI therapy is defined as follows (participants must meet at least 1 criterion): i Three months after the initiation of prior TKI therapy: No cytogenetic response (>95% Ph+) or failure to achieve CHR or new mutation ii Six months after the initiation of prior TKI therapy: BCR-ABL1IS >10% and/or Ph+ >65% or new mutation iii Twelve months after the initiation of prior TKI therapy: BCR ABL1IS >10% and/or Ph+ >35% or new mutation iv At any time after the initiation of prior TKI therapy, the development of a new BCR-ABL1 kinase domain mutation(s) v At any time after the initiation of prior TKI therapy, the development of new clonal evolution vi At any time after the initiation of prior TKI therapy, the loss of CHR, or CCyR, or the confirmed loss of MMR in 2 consecutive tests, one of which has a BCR-ABL1IS transcript level of >=1% or new mutation o] >1% of BCR-ABL1IS as shown by real-time polymerase chain reaction
Have adequate renal function as defined by the following criterion:
o] Serum creatinine \<=1.5* for institution o] Estimated >=30 milliliter per minute (mL/min) (Cockcroft-Gault formula)
Have adequate hepatic function as defined by the following criteria:
o] Total serum \<=1.5*ULN, unless due to Gilbert's syndrome o] (ALT) \<=2.5*ULN, or \<=5*ULN if leukemic infiltration of the liver is present o] Aspartate transaminase (AST) \<=2.5*ULN, or \<=5*ULN if leukemic infiltration of the liver is present
Have normal pancreatic status as defined by the following criterion:
o] Serum lipase and amylase \<=1.5*ULN
Exclusion Criteria:
Have , uncontrolled, or active cardiovascular disease, specifically including, but not restricted to:
o] Any history of myocardial infarction (MI), unstable angina, cerebrovascular accident, or (TIA) o] Any history of peripheral vascular infarction, including visceral infarction o] Any revascularization procedure, including the placement of a stent o] Congestive heart failure (CHF) ( [NYHA] class III or IV) within 6 months prior to enrollment, or (LVEF) less than lower limit of normal, per local institutional standards, within 6 months prior to enrollment o] History of clinically significant (as determined by the treating physician) atrial arrhythmia or any history of ventricular arrhythmia o] Venous thromboembolism, including deep venous thrombosis or pulmonary embolism, within 6 months prior to enrollment
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.
“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.
After a transplant from a donor, the donor’s immune cells attack the recipient’s body, often the skin, gut or liver.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Creatinine clearance (CrCl)
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
QT and QTc
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
CTCAE grade
The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.
“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Allogeneic and autologous transplant
Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GVHD (graft-versus-host disease)
After a transplant from a donor, the donor’s immune cells attack the recipient’s body, often the skin, gut or liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
TIA (transient ischaemic attack)
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
LVEF (left ventricular ejection fraction)
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HbA1c
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Biopsy and archival tissue
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants received ponatinib 45 mg orally once daily in each 28-day cycle until achievement of ≤1% BCR-ABL1IS. Once ≤1% BCR-ABL1IS was achieved, participants received reduced dose of ponatinib 15 mg orally once daily.
Drug: Ponatinib
Participants received ponatinib 30 mg orally once daily in each 28 day Cycle until achievement of ≤1% BCR-ABL1IS. Once ≤1% BCR-ABL1IS was achieved, participants received reduced dose of ponatinib 15 mg orally once daily.
Drug: Ponatinib
Participants received ponatinib 15 mg orally once daily in each 28 day Cycle.
Drug: Ponatinib
Participants received ponatinib 45 mg orally once daily in each 28-day cycle until achievement of ≤1% BCR-ABL1IS. Once ≤1% BCR-ABL1IS was achieved, participants received reduced dose of ponatinib 15 mg orally once daily.
Drug: Ponatinib
Participants received ponatinib 30 mg orally once daily in each 28 day Cycle until achievement of ≤1% BCR-ABL1IS. Once ≤1% BCR-ABL1IS was achieved, participants received reduced dose of ponatinib 15 mg orally once daily.
Drug: Ponatinib
Participants received ponatinib 15 mg orally once daily in each 28 day Cycle.
Drug: Ponatinib
Tablet, taken orally once daily.
Also known as: Iclusig, AP24534
Percentage of Participants With Molecular Response (MR2: <=1% Breakpoint Cluster Region-Abelson Transcript Level) as Measured by the International Scale (BCR-ABL1IS) at Month 12
MR2 was defined as a ratio of reverse transcribed transcript of BCR-ABL to ABL \<=1% Breakpoint Cluster Region-Abelson Transcript Level as measured by the International Scale (BCR-ABL1IS), equivalent to a 2-log reduction in transcript.
Time frame: 12 months after the first dose of study treatment
Percentage of Participants With Major Molecular Response (MMR/MR3)
MMR/MR3 was defined as a ratio of reverse transcribed transcript of BCR-ABL to ABL ≤0.1% on the international scale (equivalent to a 3-log reduction in transcript).
Time frame: 12, 24 and 60 months after the first dose of study treatment
Percentage of Participants With Major Cytogenetic Response (MCyR)
MCyR was defined as percentage of participants with complete cytogenetic response (CCyR) or partial cytogenetic response (PCyR). Cytogenetic response is the percentage of Philadelphia chromosome positive (Ph+) metaphases in bone marrow (BM). Response is further defined as MCyR: CCyR or PCyR, where CCyR: 0% Ph + metaphases; PCyR: \>0 to 35% Ph + metaphases.
Time frame: 12 months after the first dose of study treatment
Duration of Major Molecular Response (MMR/MR3)
Duration of MMR/MR3 was defined as the interval between the first assessment at which the criteria for \<=0.1% MMR were met until the earliest date at which loss of \<=0.1% MMR occurred, or the criteria for progression were met. Progression to accelerated phase (AP) was defined as: \>= 15% and \<30% blasts in peripheral blood or bone marrow or \>=20% basophils in peripheral blood or bone marrow or \>=30% blasts + promyelocytes in peripheral blood or bone marrow (but \<30% blasts) or \<100\*109 platelets per liter (/L) in peripheral blood unrelated to therapy or cytogenetic, genetic evidence of clonal evolution, and no extramedullary disease. Progression to blast phase (BP) was defined as: \>=30% blasts in peripheral blood or bone marrow or extramedullary disease other than hepatosplenomegaly.
Time frame: Baseline up to approximately 8.9 years
Percentage of Participants With Adjusted Incidence Rates for Treatment Emergent Arterial Occlusive Events (AOEs), Venous Thrombotic Events (VTEs), Adverse Events (AEs), and Serious AEs (SAEs)
Percentage of participants with adjusted incidence rates who developed AOEs and VTEs were categorized according to arterial occlusive events and venous thrombotic events. AE is any untoward medical occurrence in participant administered medicinal investigational drug. Untoward medical occurrence does not necessarily have to have causal relationship with treatment. SAE is any untoward medical occurrence that results in death; is life-threatening; requires inpatient hospitalization or prolongation of present hospitalization; results in persistent or significant disability/incapacity; is congenital anomaly/birth defect/is medically important event that may not be immediately life-threatening/result in death or hospitalization, but may jeopardize participant/may require intervention to prevent one of other outcomes listed in definition above, or involves suspected transmission via a medicinal product of an infectious agent.
Time frame: From first dose up to 30 days after last dose of the study drug (up to approximately 9.8 years)
Percentage of Participants With Complete Cytogenetic Response (CCyR)
Cytogenetic response was defined as the percentage of Ph+ metaphases in bone marrow (peripheral blood may not be used), with a review of a minimum of 20 metaphases. CCyR was defined as 0% Ph+ metaphases.
Time frame: Month 12
Percentage of Participants With Molecular Response 4 (MR4) and Molecular Response 4.5 (MR4.5)
MR4 was defined as \<=0.01% BCR-ABL1IS. MR 4.5was defined as \<=0.0032% BCR-ALB1IS. MR4 and MR4.5 by each time point means the best outcome up to each time point after randomization.
Time frame: Up to approximately 9.5 years
Percentage of Participants With Molecular Response 1 (MR1)
MR1 was defined as percentage of participants achieving a ratio of \<=10% Breakpoint Cluster Region-Abelson (BCR-ABL1) transcripts on the international scale. MR1 is molecular response with 1-log reduction in transcript.
Time frame: 3 months after the first dose of study treatment
Percentage of Participants With Complete Hematologic Response (CHR)
CHR was defined as achieving all of the following measurements: white blood cells (WBC) \<= institutional upper limit of normal (ULN), platelets less than (\<)450,000 per cubic millimeter (/mm\^3), no blasts or promyelocytes in peripheral blood, \<5% myelocytes plus metamyelocytes in peripheral blood, basophils in peripheral blood \<5%, and no extramedullary involvement (including no hepatomegaly or splenomegaly).
Time frame: 3 months after the first dose of study treatment
Percentage of Participants With Treatment Emergent AEs Leading to Treatment Discontinuation, Dose Reduction and Dose Interruption
An AE is defined as any untoward medical occurrence in a clinical investigation participant administered a drug; it does not necessarily have to have a causal relationship with this treatment. A TEAE is defined as an adverse event with an onset that occurs after receiving study drug.
Time frame: Up to approximately 9.8 years
Kaplan-Meier Estimate of Duration of Response (DOR) of <=1% BCR-ABL1 IS (MR2) at Months 12 and 24
DOR (≤1% BCR-ABL1IS) is defined as interval between first assessment at which criteria for ≤1% BCR-ABL1IS are met until earliest date at which loss of ≤1% BCR-ABL1IS occurs, or criteria for progression accelerated phase (AP) or blast Phase (BP) of chronic myeloid leukemia (CML) are met. Loss of ≤1% BCR-ABL1IS is an increase to \>1% of BCR-ABL1IS. Progression to AP: ≥15% and \<30% blasts in peripheral blood or bone marrow or ≥20% basophils in peripheral blood or bone marrow or ≥30% blasts + promyelocytes in peripheral blood or bone marrow (but \<30% blasts) or \<100\*109 platelets per liter in peripheral blood unrelated to therapy or cytogenetic, genetic evidence of clonal evolution, and no extramedullary disease. Progression to BP: ≥30% blasts in peripheral blood or bone marrow or extramedullary disease other than hepatosplenomegaly. Kaplan-Meier method was used for analysis of percentage of participants who achieved DOR of 12 and 24 months.
Time frame: 12 and 24 months after the first dose of study treatment
Kaplan-Meier Estimate of Duration of Response (DOR) of Major Molecular Response (MMR/MR3)
Duration of MMR/MR3 is defined as interval between first assessment at which criteria for MMR are met until earliest date at which loss of MMR occurs, or criteria for progression (progression to AP or BP of CML) are met. Participants remaining in MMR will be censored at last date at which criteria for MMR are met. Loss of MMR is an increase to \>0.1% of BCR-ABL1IS. Progression to AP: \>= 15% and \<30% blasts in peripheral blood or bone marrow or \>=20% basophils in peripheral blood or bone marrow or \>=30% blasts+promyelocytes in peripheral blood or bone marrow (but \<30% blasts) or \<100\*109 platelets/L in peripheral blood unrelated to therapy or cytogenetic, genetic evidence of clonal evolution, and no extramedullary disease. Progression to BP: \>=30% blasts in peripheral blood or bone marrow or extramedullary disease other than hepatosplenomegaly. Kaplan-Meier method was used for analysis of percentage of participants who achieved DOR of 12 and 24 months.
Time frame: 12 and 24 months after the first dose of study treatment
Duration of Response in MR2 Responders
Duration of response in "responders" was defined as any participants who achieved ≤1% BCR-ABL1IS (MR2) at any time during the study. Responders were defined as those participants who met all of the following: were randomized and treated, responded at 12 months after the initiation of study treatment, and underwent baseline polymerase chain reaction (PCR) assessment.
Time frame: Baseline up to approximately 8.9 years
Time to Response (MR2)
Time to response was defined as the time interval from the date of the first dose of the study drug until the initial observation of CR or PR for participants with confirmed CR/PR. Response was defined as any participants who achieved ≤1% BCR-ABL1IS (MR2) at any time during the study. CR for target lesion: disappearance of all extranodal lesions and all pathological lymph nodes must have decreased to \<10 mm in short axis. CR for non-target lesion: Disappearance of all extranodal non-target lesions, all lymph nodes must be non-pathological in size (\<10mm short axis) and normalization of tumor marker level. PR: at least a 30% decrease in the SLD of target lesions, taking as reference the Baseline sum diameters.
Time frame: Baseline up to approximately 5 years
Percentage of Participants With Progression to Accelerated Phase (AP)-Chronic Myeloid Leukemia (CML) or Blast Phase (BP)-CML
Progression to AP is defined as: \>=15% and \<30% blasts in peripheral blood or bone marrow or \>=20% basophils in peripheral blood or bone marrow or \>=30% blasts + promyelocytes in peripheral blood or bone marrow (but \<30% blasts) or \<100\*109 platelets/L in peripheral blood unrelated to therapy or cytogenetic, genetic evidence of clonal evolution, and no extramedullary disease. Progression to BP is defined as: \>=30% blasts in peripheral blood or bone marrow or extramedullary disease other than hepatosplenomegaly.
Time frame: From first dose date of study treatment up to approximately 8.9 years
Progression-free Survival (PFS)
PFS was defined as the interval between the first dose date of study treatment and the first date at which the criteria for progression were met (progression to the AP or BP of CML), or death due to any cause, censored at the last response assessment. Progression to AP was defined as: \>=15% and \<30% blasts in peripheral blood or bone marrow or \>=20% basophils in peripheral blood or bone marrow or \>=30% blasts + promyelocytes in peripheral blood or bone marrow (but \<30% blasts) or \<100\*109 platelets/L in peripheral blood unrelated to therapy or cytogenetic, genetic evidence of clonal evolution, and no extramedullary disease. Progression to BP was defined as: \>=30% blasts in peripheral blood or bone marrow or extramedullary disease other than hepatosplenomegaly.
Time frame: Up to approximately 8.9 years
Overall Survival (OS)
OS was defined as the interval between the first dose of study treatment and death due to any cause, censored at the last contact date when the participant was alive.
Time frame: Up to approximately 8.9 years
Participants took part in the study at 61 investigative sites globally from 13 July 2015 to 23 April 2025.
| Milestone | Treatment Period: Cohort A: Ponatinib 45 mg | Treatment Period: Cohort B: Ponatinib 30 mg | Treatment Period: Cohort C: Ponatinib 15 mg | Close-out Period: Cohort A: Ponatinib 45 mg | Close-out Period: Cohort B: Ponatinib 30 mg | Close-out Period: Cohort C: Ponatinib 15 mg |
|---|---|---|---|---|---|---|
| Started | 94 | 95 | 94 | 0 | 0 | 0 |
| Treated (safety population) | 94 | 94 | 94 | 0 | 0 | 0 |
| Completed | 0 | 0 | 0 | 0 | 0 | 0 |
| Not completed | 94 | 95 | 94 | 0 | 0 | 0 |
| Withdrew: Participants never treated | 0 | 1 | 0 | 0 | 0 | 0 |
| Withdrew: Ongoing at the end of treatment period | 27 | 17 | 17 | 0 | 0 | 0 |
| Withdrew: Adverse event | 20 | 19 | 17 | 0 | 0 | 0 |
| Withdrew: Progressive disease | 9 | 10 | 7 | 0 | 0 | 0 |
| Withdrew: Death | 4 | 2 | 3 | 0 | 0 | 0 |
| Withdrew: Lack of efficacy | 16 | 22 | 28 | 0 | 0 | 0 |
| Withdrew: Non-compliance with study drug | 0 | 2 | 1 | 0 | 0 | 0 |
| Withdrew: Lost to follow-up | 3 | 1 | 1 | 0 | 0 | 0 |
| Withdrew: Pregnancy | 1 | 1 | 0 | 0 | 0 | 0 |
| Withdrew: Transitioned to post-trial ponatinib access | 5 | 0 | 5 | 0 | 0 | 0 |
| Withdrew: Physician decision | 2 | 9 | 8 | 0 | 0 | 0 |
| Withdrew: Withdrawal by subject | 6 | 9 | 7 | 0 | 0 | 0 |
| Withdrew: Reason not specified | 1 | 2 | 0 | 0 | 0 | 0 |
| Milestone | Treatment Period: Cohort A: Ponatinib 45 mg | Treatment Period: Cohort B: Ponatinib 30 mg | Treatment Period: Cohort C: Ponatinib 15 mg | Close-out Period: Cohort A: Ponatinib 45 mg | Close-out Period: Cohort B: Ponatinib 30 mg | Close-out Period: Cohort C: Ponatinib 15 mg |
|---|---|---|---|---|---|---|
| Started | 0 | 0 | 0 | 27 | 17 | 17 |
| Completed | 0 | 0 | 0 | 0 | 0 | 0 |
| Not completed | 0 | 0 | 0 | 27 | 17 | 17 |
| Withdrew: Transitioned to post-trial ponatinib access | 0 | 0 | 0 | 24 | 15 | 17 |
| Withdrew: Adverse event | 0 | 0 | 0 | 2 | 0 | 0 |
| Withdrew: Progressive disease | 0 | 0 | 0 | 1 | 0 | 0 |
| Withdrew: Physician decision | 0 | 0 | 0 | 0 | 1 | 0 |
| Withdrew: Withdrawal by subject | 0 | 0 | 0 | 0 | 1 | 0 |
MR2 was defined as a ratio of reverse transcribed transcript of BCR-ABL to ABL \<=1% Breakpoint Cluster Region-Abelson Transcript Level as measured by the International Scale (BCR-ABL1IS), equivalent to a 2-log reduction in transcript.
| percentage of participants | Treatment Period: Cohort A: Ponatinib 45 mg | Treatment Period: Cohort B: Ponatinib 30 mg | Treatment Period: Cohort C: Ponatinib 15 mg |
|---|---|---|---|
| Percentage of Participants With Molecular Response (MR2: <=1% Breakpoint Cluster Region-Abelson Transcript Level) as Measured by the International Scale (BCR-ABL1IS) at Month 12 | 44.1 (31.7 to 57.0) | 29.0 (18.4 to 41.6) | 23.1 (13.4 to 35.3) |
MMR/MR3 was defined as a ratio of reverse transcribed transcript of BCR-ABL to ABL ≤0.1% on the international scale (equivalent to a 3-log reduction in transcript).
| percentage of participants | Treatment Period: Cohort A: Ponatinib 45 mg | Treatment Period: Cohort B: Ponatinib 30 mg | Treatment Period: Cohort C: Ponatinib 15 mg |
|---|---|---|---|
| 12 Months | 17.2 | 20.4 | 16.5 |
| 24 Months | 24.7 | 15.1 | 19.8 |
| 60 Months | 46.2 | 29.0 | 24.2 |
MCyR was defined as percentage of participants with complete cytogenetic response (CCyR) or partial cytogenetic response (PCyR). Cytogenetic response is the percentage of Philadelphia chromosome positive (Ph+) metaphases in bone marrow (BM). Response is further defined as MCyR: CCyR or PCyR, where CCyR: 0% Ph + metaphases; PCyR: \>0 to 35% Ph + metaphases.
| percentage of participants | Treatment Period: Cohort A: Ponatinib 45 mg | Treatment Period: Cohort B: Ponatinib 30 mg | Treatment Period: Cohort C: Ponatinib 15 mg |
|---|---|---|---|
| Percentage of Participants With Major Cytogenetic Response (MCyR) | 48.4 (37.7 to 59.1) | 30.0 (20.8 to 40.6) | 43.8 (33.3 to 54.7) |
Duration of MMR/MR3 was defined as the interval between the first assessment at which the criteria for \<=0.1% MMR were met until the earliest date at which loss of \<=0.1% MMR occurred, or the criteria for progression were met. Progression to accelerated phase (AP) was defined as: \>= 15% and \<30% blasts in peripheral blood or bone marrow or \>=20% basophils in peripheral blood or bone marrow or \>=30% blasts + promyelocytes in peripheral blood or bone marrow (but \<30% blasts) or \<100\*109 platelets per liter (/L) in peripheral blood unrelated to therapy or cytogenetic, genetic evidence of clonal evolution, and no extramedullary disease. Progression to blast phase (BP) was defined as: \>=30% blasts in peripheral blood or bone marrow or extramedullary disease other than hepatosplenomegaly.
| months | Treatment Period: Cohort A: Ponatinib 45 mg | Treatment Period: Cohort B: Ponatinib 30 mg | Treatment Period: Cohort C: Ponatinib 15 mg |
|---|---|---|---|
| Duration of Major Molecular Response (MMR/MR3) | NA (NA to NA) | NA (27.3 to NA) | NA (NA to NA) |
Percentage of participants with adjusted incidence rates who developed AOEs and VTEs were categorized according to arterial occlusive events and venous thrombotic events. AE is any untoward medical occurrence in participant administered medicinal investigational drug. Untoward medical occurrence does not necessarily have to have causal relationship with treatment. SAE is any untoward medical occurrence that results in death; is life-threatening; requires inpatient hospitalization or prolongation of present hospitalization; results in persistent or significant disability/incapacity; is congenital anomaly/birth defect/is medically important event that may not be immediately life-threatening/result in death or hospitalization, but may jeopardize participant/may require intervention to prevent one of other outcomes listed in definition above, or involves suspected transmission via a medicinal product of an infectious agent.
| percentage of participants | Treatment Period: Cohort A: Ponatinib 45 mg | Treatment Period: Cohort B: Ponatinib 30 mg | Treatment Period: Cohort C: Ponatinib 15 mg | Close-out Period: Cohort A: Ponatinib 45 mg | Close-out Period: Cohort B: Ponatinib 30 mg | Close-out Period: Cohort C: Ponatinib 15 mg |
|---|---|---|---|---|---|---|
| AOEs | 13.8 | 9.6 | 5.3 | 3.7 | 11.8 | 0 |
| VTEs | 1.1 | 1.1 | 1.1 | 0 | 0 | 0 |
| AEs | 100.0 | 97.9 | 97.9 | 74.1 | 94.1 | 76.5 |
| SAEs | 40.4 | 35.1 | 41.5 | 3.7 | 17.6 | 0 |
Cytogenetic response was defined as the percentage of Ph+ metaphases in bone marrow (peripheral blood may not be used), with a review of a minimum of 20 metaphases. CCyR was defined as 0% Ph+ metaphases.
| percentage of participants | Treatment Period: Cohort A: Ponatinib 45 mg | Treatment Period: Cohort B: Ponatinib 30 mg | Treatment Period: Cohort C: Ponatinib 15 mg |
|---|---|---|---|
| Percentage of Participants With Complete Cytogenetic Response (CCyR) | 34.1 | 18.9 | 29.2 |
MR4 was defined as \<=0.01% BCR-ABL1IS. MR 4.5was defined as \<=0.0032% BCR-ALB1IS. MR4 and MR4.5 by each time point means the best outcome up to each time point after randomization.
| percentage of participants | Treatment Period: Cohort A: Ponatinib 45 mg | Treatment Period: Cohort B: Ponatinib 30 mg | Treatment Period: Cohort C: Ponatinib 15 mg |
|---|---|---|---|
| MR4: 3 Months | 1.1 (0.0 to 5.8) | 1.1 (0.0 to 5.8) | 0 (0.0 to 4.0) |
| MR4: 6 Months | 3.2 (0.7 to 9.1) | 2.2 (0.3 to 7.6) | 3.3 (0.7 to 9.3) |
| MR4: 9 Months | 5.4 (1.8 to 12.1) | 8.6 (3.8 to 16.2) | 5.5 (1.8 to 12.4) |
| MR4: 12 Months | 6.5 (2.4 to 13.5) | 9.7 (4.5 to 17.6) | 7.7 (3.1 to 15.2) |
| MR4: 15 Months | 6.5 (2.4 to 13.5) | 9.7 (4.5 to 17.6) | 8.8 (3.9 to 16.6) |
| MR4: 18 Months | 7.5 (3.1 to 14.9) | 9.7 (4.5 to 17.6) | 12.1 (6.2 to 20.6) |
| MR4: 21 Months | 7.5 (3.1 to 14.9) | 11.8 (6.1 to 20.2) | 12.1 (6.2 to 20.6) |
| MR4: 24 Months | 10.8 (5.3 to 18.9) | 12.9 (6.8 to 21.5) | 12.1 (6.2 to 20.6) |
| MR4: 27 Months | 11.8 (6.1 to 20.2) | 15.1 (8.5 to 24.0) | 13.2 (7.0 to 21.9) |
| MR4: 30 Months | 12.9 (6.8 to 21.5) | 15.1 (8.5 to 24.0) | 13.2 (7.0 to 21.9) |
| MR4: 33 Months | 16.1 (9.3 to 25.2) | 15.1 (8.5 to 24.0) | 13.2 (7.0 to 21.9) |
| MR4: 36 Months | 18.3 (11.0 to 27.6) | 15.1 (8.5 to 24.0) | 14.3 (7.8 to 23.2) |
| MR4: 39 Months | 19.4 (11.9 to 28.9) | 15.1 (8.5 to 24.0) | 17.6 (10.4 to 27.0) |
| MR4: 42 Months | 19.4 (11.9 to 28.9) | 15.1 (8.5 to 24.0) | 17.6 (10.4 to 27.0) |
| MR4: 45 Months | 19.4 (11.9 to 28.9) | 16.1 (9.3 to 25.2) | 18.7 (11.3 to 28.2) |
| MR4: 48 Months | 20.4 (12.8 to 30.1) | 16.1 (9.3 to 25.2) | 18.7 (11.3 to 28.2) |
| MR4: 51 Months | 21.5 (13.7 to 31.2) | 17.2 (10.2 to 26.4) | 18.7 (11.3 to 28.2) |
| MR4: 54 Months | 21.5 (13.7 to 31.2) | 17.2 (10.2 to 26.4) | 18.7 (11.3 to 28.2) |
| MR4: 57 Months | 21.5 (13.7 to 31.2) | 18.3 (11.0 to 27.6) | 18.7 (11.3 to 28.2) |
| MR4: 60 Months | 23.7 (15.5 to 33.6) | 18.3 (11.0 to 27.6) | 18.7 (11.3 to 28.2) |
| MR4: 63 Months | 23.7 (15.5 to 33.6) | 18.3 (11.0 to 27.6) | 18.7 (11.3 to 28.2) |
| MR4: 66 Months | 24.7 (16.4 to 34.8) | 19.4 (11.9 to 28.9) | 18.7 (11.3 to 28.2) |
| MR4: 69 Months | 24.7 (16.4 to 34.8) | 19.4 (11.9 to 28.9) | 18.7 (11.3 to 28.2) |
| MR4: 72 Months | 24.7 (16.4 to 34.8) | 19.4 (11.9 to 28.9) | 18.7 (11.3 to 28.2) |
| MR4: 75 Months | 24.7 (16.4 to 34.8) | 19.4 (11.9 to 28.9) | 19.8 (12.2 to 29.4) |
| MR4: 78 Months | 25.8 (17.3 to 35.9) | 19.4 (11.9 to 28.9) | 19.8 (12.2 to 29.4) |
| MR4: 81 Months | 25.8 (17.3 to 35.9) | 19.4 (11.9 to 28.9) | 19.8 (12.2 to 29.4) |
| MR4: 84 Months | 25.8 (17.3 to 35.9) | 19.4 (11.9 to 28.9) | 19.8 (12.2 to 29.4) |
| MR4: 87 Months | 25.8 (17.3 to 35.9) | 19.4 (11.9 to 28.9) | 19.8 (12.2 to 29.4) |
| MR4: 90 Months | 25.8 (17.3 to 35.9) | 19.4 (11.9 to 28.9) | 19.8 (12.2 to 29.4) |
| MR4: 93 Months | 25.8 (17.3 to 35.9) | 19.4 (11.9 to 28.9) | 19.8 (12.2 to 29.4) |
| MR4: 96 Months | 25.8 (17.3 to 35.9) | 19.4 (11.9 to 28.9) | 19.8 (12.2 to 29.4) |
| MR4: 99 Months | 25.8 (17.3 to 35.9) | 19.4 (11.9 to 28.9) | 19.8 (12.2 to 29.4) |
| MR4: 102 Months | 25.8 (17.3 to 35.9) | 19.4 (11.9 to 28.9) | 19.8 (12.2 to 29.4) |
| MR4: 105 Months | 25.8 (17.3 to 35.9) | 19.4 (11.9 to 28.9) | 19.8 (12.2 to 29.4) |
| MR4: 108 Months | 25.8 (17.3 to 35.9) | 19.4 (11.9 to 28.9) | 19.8 (12.2 to 29.4) |
| MR4: 111 Months | 25.8 (17.3 to 35.9) | 19.4 (11.9 to 28.9) | 19.8 (12.2 to 29.4) |
| MR4: 114 Months | 25.8 (17.3 to 35.9) | 19.4 (11.9 to 28.9) | 19.8 (12.2 to 29.4) |
| MR4.5: 3 Months | 1.1 (0.0 to 5.8) | 0 (0.0 to 3.9) | 0 (0.0 to 4.0) |
| MR4.5: 6 Months | 1.1 (0.0 to 5.8) | 1.1 (0.0 to 5.8) | 0 (0.0 to 4.0) |
| MR4.5: 9 Months | 2.2 (0.3 to 7.6) | 3.2 (0.7 to 9.1) | 2.2 (0.3 to 7.7) |
| MR4.5: 12 Months | 4.3 (1.2 to 10.6) | 6.5 (2.4 to 13.5) | 2.2 (0.3 to 7.7) |
| MR4.5: 15 Months | 4.3 (1.2 to 10.6) | 7.5 (3.1 to 14.9) | 3.3 (0.7 to 9.3) |
| MR4.5: 18 Months | 5.4 (1.8 to 12.1) | 7.5 (3.1 to 14.9) | 4.4 (1.2 to 10.9) |
| MR4.5: 21 Months | 5.4 (1.8 to 12.1) | 7.5 (3.1 to 14.9) | 6.6 (2.5 to 13.8) |
| MR4.5: 24 Months | 5.4 (1.8 to 12.1) | 8.6 (3.8 to 16.2) | 8.8 (3.9 to 16.6) |
| MR4.5: 27 Months | 5.4 (1.8 to 12.1) | 8.6 (3.8 to 16.2) | 8.8 (3.9 to 16.6) |
| MR4.5: 30 Months | 6.5 (2.4 to 13.5) | 8.6 (3.8 to 16.2) | 9.9 (4.6 to 17.9) |
| MR4.5: 33 Months | 6.5 (2.4 to 13.5) | 8.6 (3.8 to 16.2) | 9.9 (4.6 to 17.9) |
| MR4.5: 36 Months | 11.8 (6.1 to 20.2) | 9.7 (4.5 to 17.6) | 11.0 (5.4 to 19.3) |
| MR4.5: 39 Months | 11.8 (6.1 to 20.2) | 9.7 (4.5 to 17.6) | 12.1 (6.2 to 20.6) |
| MR4.5: 42 Months | 11.8 (6.1 to 20.2) | 10.8 (5.3 to 18.9) | 13.2 (7.0 to 21.9) |
| MR4.5: 45 Months | 11.8 (6.1 to 20.2) | 10.8 (5.3 to 18.9) | 15.4 (8.7 to 24.5) |
| MR4.5: 48 Months | 11.8 (6.1 to 20.2) | 10.8 (5.3 to 18.9) | 15.4 (8.7 to 24.5) |
| MR4.5: 51 Months | 11.8 (6.1 to 20.2) | 12.9 (6.8 to 21.5) | 15.4 (8.7 to 24.5) |
| MR4.5: 54 Months | 12.9 (6.8 to 21.5) | 12.9 (6.8 to 21.5) | 15.4 (8.7 to 24.5) |
| MR4.5: 57 Months | 12.9 (6.8 to 21.5) | 14.0 (7.7 to 22.7) | 15.4 (8.7 to 24.5) |
| MR4.5: 60 Months | 12.9 (6.8 to 21.5) | 14.0 (7.7 to 22.7) | 15.4 (8.7 to 24.5) |
| MR4.5: 63 Months | 12.9 (6.8 to 21.5) | 15.1 (8.5 to 24.0) | 15.4 (8.7 to 24.5) |
| MR4.5: 66 Months | 12.9 (6.8 to 21.5) | 15.1 (8.5 to 24.0) | 15.4 (8.7 to 24.5) |
| MR4.5: 69 Months | 12.9 (6.8 to 21.5) | 15.1 (8.5 to 24.0) | 16.5 (9.5 to 25.7) |
| MR4.5: 72 Months | 14.0 (7.7 to 22.7) | 15.1 (8.5 to 24.0) | 17.6 (10.4 to 27.0) |
| MR4.5: 75 Months | 14.0 (7.7 to 22.7) | 15.1 (8.5 to 24.0) | 17.6 (10.4 to 27.0) |
| MR4.5: 78 Months | 14.0 (7.7 to 22.7) | 15.1 (8.5 to 24.0) | 17.6 (10.4 to 27.0) |
| MR4.5: 81 Months | 14.0 (7.7 to 22.7) | 15.1 (8.5 to 24.0) | 17.6 (10.4 to 27.0) |
| MR4.5: 84 Months | 15.1 (8.5 to 24.0) | 15.1 (8.5 to 24.0) | 17.6 (10.4 to 27.0) |
| MR4.5: 87 Months | 15.1 (8.5 to 24.0) | 15.1 (8.5 to 24.0) | 17.6 (10.4 to 27.0) |
| MR4.5: 90 Months | 15.1 (8.5 to 24.0) | 15.1 (8.5 to 24.0) | 17.6 (10.4 to 27.0) |
| MR4.5: 93 Months | 15.1 (8.5 to 24.0) | 15.1 (8.5 to 24.0) | 17.6 (10.4 to 27.0) |
| MR4.5: 96 Months | 15.1 (8.5 to 24.0) | 15.1 (8.5 to 24.0) | 17.6 (10.4 to 27.0) |
| MR4.5: 99 Months | 15.1 (8.5 to 24.0) | 15.1 (8.5 to 24.0) | 17.6 (10.4 to 27.0) |
| MR4.5: 102 Months | 15.1 (8.5 to 24.0) | 15.1 (8.5 to 24.0) | 17.6 (10.4 to 27.0) |
| MR4.5: 105 Months | 15.1 (8.5 to 24.0) | 15.1 (8.5 to 24.0) | 17.6 (10.4 to 27.0) |
| MR4.5: 108 Months | 15.1 (8.5 to 24.0) | 15.1 (8.5 to 24.0) | 17.6 (10.4 to 27.0) |
| MR4.5: 111 Months | 15.1 (8.5 to 24.0) | 15.1 (8.5 to 24.0) | 17.6 (10.4 to 27.0) |
| MR4.5: 114 Months | 15.1 (8.5 to 24.0) | 15.1 (8.5 to 24.0) | 17.6 (10.4 to 27.0) |
MR1 was defined as percentage of participants achieving a ratio of \<=10% Breakpoint Cluster Region-Abelson (BCR-ABL1) transcripts on the international scale. MR1 is molecular response with 1-log reduction in transcript.
| percentage of participants | Treatment Period: Cohort A: Ponatinib 45 mg | Treatment Period: Cohort B: Ponatinib 30 mg | Treatment Period: Cohort C: Ponatinib 15 mg |
|---|---|---|---|
| Percentage of Participants With Molecular Response 1 (MR1) | 52.7 | 44.1 | 42.9 |
CHR was defined as achieving all of the following measurements: white blood cells (WBC) \<= institutional upper limit of normal (ULN), platelets less than (\<)450,000 per cubic millimeter (/mm\^3), no blasts or promyelocytes in peripheral blood, \<5% myelocytes plus metamyelocytes in peripheral blood, basophils in peripheral blood \<5%, and no extramedullary involvement (including no hepatomegaly or splenomegaly).
| percentage of participants | Treatment Period: Cohort A: Ponatinib 45 mg | Treatment Period: Cohort B: Ponatinib 30 mg | Treatment Period: Cohort C: Ponatinib 15 mg |
|---|---|---|---|
| Percentage of Participants With Complete Hematologic Response (CHR) | 87.2 (78.8 to 93.2) | 81.1 (71.7 to 88.4) | 81.9 (72.6 to 89.1) |
An AE is defined as any untoward medical occurrence in a clinical investigation participant administered a drug; it does not necessarily have to have a causal relationship with this treatment. A TEAE is defined as an adverse event with an onset that occurs after receiving study drug.
| percentage of participants | Treatment Period: Cohort A: Ponatinib 45 mg | Treatment Period: Cohort B: Ponatinib 30 mg | Treatment Period: Cohort C: Ponatinib 15 mg | Close-out Period: Cohort A: Ponatinib 45 mg | Close-out Period: Cohort B: Ponatinib 30 mg | Close-out Period: Cohort C: Ponatinib 15 mg |
|---|---|---|---|---|---|---|
| TEAEs Leading to Treatment Discontinuation | 24.5 | 19.1 | 20.2 | 3.7 | 0 | 0 |
| TEAEs Leading to Dose Reduction | 51.1 | 39.4 | 34.0 | 3.7 | 0 | 0 |
| TEAEs Leading to Dose Interruption | 80.9 | 68.1 | 66.0 | 7.4 | 11.8 | 5.9 |
DOR (≤1% BCR-ABL1IS) is defined as interval between first assessment at which criteria for ≤1% BCR-ABL1IS are met until earliest date at which loss of ≤1% BCR-ABL1IS occurs, or criteria for progression accelerated phase (AP) or blast Phase (BP) of chronic myeloid leukemia (CML) are met. Loss of ≤1% BCR-ABL1IS is an increase to \>1% of BCR-ABL1IS. Progression to AP: ≥15% and \<30% blasts in peripheral blood or bone marrow or ≥20% basophils in peripheral blood or bone marrow or ≥30% blasts + promyelocytes in peripheral blood or bone marrow (but \<30% blasts) or \<100\*109 platelets per liter in peripheral blood unrelated to therapy or cytogenetic, genetic evidence of clonal evolution, and no extramedullary disease. Progression to BP: ≥30% blasts in peripheral blood or bone marrow or extramedullary disease other than hepatosplenomegaly. Kaplan-Meier method was used for analysis of percentage of participants who achieved DOR of 12 and 24 months.
| percentage of participants | Treatment Period: Cohort A: Ponatinib 45 mg | Treatment Period: Cohort B: Ponatinib 30 mg | Treatment Period: Cohort C: Ponatinib 15 mg |
|---|---|---|---|
| Month 12 | 79.13 (64.5 to 88.3) | 79.20 (61.2 to 89.5) | 90.10 (72.4 to 96.7) |
| Month 24 | 73.89 (59.9 to 83.6) | 77.91 (60.6 to 88.3) | 88.31 (71.8 to 95.4) |
Duration of MMR/MR3 is defined as interval between first assessment at which criteria for MMR are met until earliest date at which loss of MMR occurs, or criteria for progression (progression to AP or BP of CML) are met. Participants remaining in MMR will be censored at last date at which criteria for MMR are met. Loss of MMR is an increase to \>0.1% of BCR-ABL1IS. Progression to AP: \>= 15% and \<30% blasts in peripheral blood or bone marrow or \>=20% basophils in peripheral blood or bone marrow or \>=30% blasts+promyelocytes in peripheral blood or bone marrow (but \<30% blasts) or \<100\*109 platelets/L in peripheral blood unrelated to therapy or cytogenetic, genetic evidence of clonal evolution, and no extramedullary disease. Progression to BP: \>=30% blasts in peripheral blood or bone marrow or extramedullary disease other than hepatosplenomegaly. Kaplan-Meier method was used for analysis of percentage of participants who achieved DOR of 12 and 24 months.
| percentage of participants | Treatment Period: Cohort A: Ponatinib 45 mg | Treatment Period: Cohort B: Ponatinib 30 mg | Treatment Period: Cohort C: Ponatinib 15 mg |
|---|---|---|---|
| Month 12 | 88.97 (69.5 to 96.3) | 93.33 (61.3 to 99.0) | 94.74 (68.1 to 99.2) |
| Month 24 | 82.94 (67.4 to 91.5) | 74.77 (52.1 to 87.8) | 95.45 (71.9 to 99.3) |
Duration of response in "responders" was defined as any participants who achieved ≤1% BCR-ABL1IS (MR2) at any time during the study. Responders were defined as those participants who met all of the following: were randomized and treated, responded at 12 months after the initiation of study treatment, and underwent baseline polymerase chain reaction (PCR) assessment.
| months | Treatment Period: Cohort A: Ponatinib 45 mg | Treatment Period: Cohort B: Ponatinib 30 mg | Treatment Period: Cohort C: Ponatinib 15 mg |
|---|---|---|---|
| Duration of Response in MR2 Responders | NA (61.5 to NA) | NA (NA to NA) | NA (NA to NA) |
Time to response was defined as the time interval from the date of the first dose of the study drug until the initial observation of CR or PR for participants with confirmed CR/PR. Response was defined as any participants who achieved ≤1% BCR-ABL1IS (MR2) at any time during the study. CR for target lesion: disappearance of all extranodal lesions and all pathological lymph nodes must have decreased to \<10 mm in short axis. CR for non-target lesion: Disappearance of all extranodal non-target lesions, all lymph nodes must be non-pathological in size (\<10mm short axis) and normalization of tumor marker level. PR: at least a 30% decrease in the SLD of target lesions, taking as reference the Baseline sum diameters.
| months | Treatment Period: Cohort A: Ponatinib 45 mg | Treatment Period: Cohort B: Ponatinib 30 mg | Treatment Period: Cohort C: Ponatinib 15 mg |
|---|---|---|---|
| Time to Response (MR2) | 6.00 (5.8 to 6.1) | 3.11 (3.0 to 6.0) | 6.18 (3.1 to 14.5) |
Progression to AP is defined as: \>=15% and \<30% blasts in peripheral blood or bone marrow or \>=20% basophils in peripheral blood or bone marrow or \>=30% blasts + promyelocytes in peripheral blood or bone marrow (but \<30% blasts) or \<100\*109 platelets/L in peripheral blood unrelated to therapy or cytogenetic, genetic evidence of clonal evolution, and no extramedullary disease. Progression to BP is defined as: \>=30% blasts in peripheral blood or bone marrow or extramedullary disease other than hepatosplenomegaly.
| percentage of participants | Treatment Period: Cohort A: Ponatinib 45 mg | Treatment Period: Cohort B: Ponatinib 30 mg | Treatment Period: Cohort C: Ponatinib 15 mg |
|---|---|---|---|
| Progressed to AP-CML | 11.7 | 11.6 | 13.8 |
| Progressed to BP-CML | 3.2 | 1.1 | 2.1 |
PFS was defined as the interval between the first dose date of study treatment and the first date at which the criteria for progression were met (progression to the AP or BP of CML), or death due to any cause, censored at the last response assessment. Progression to AP was defined as: \>=15% and \<30% blasts in peripheral blood or bone marrow or \>=20% basophils in peripheral blood or bone marrow or \>=30% blasts + promyelocytes in peripheral blood or bone marrow (but \<30% blasts) or \<100\*109 platelets/L in peripheral blood unrelated to therapy or cytogenetic, genetic evidence of clonal evolution, and no extramedullary disease. Progression to BP was defined as: \>=30% blasts in peripheral blood or bone marrow or extramedullary disease other than hepatosplenomegaly.
| months | Treatment Period: Cohort A: Ponatinib 45 mg | Treatment Period: Cohort B: Ponatinib 30 mg | Treatment Period: Cohort C: Ponatinib 15 mg |
|---|---|---|---|
| Progression-free Survival (PFS) | NA (63.5 to NA) | 75.04 (45.0 to NA) | NA (45.8 to NA) |
OS was defined as the interval between the first dose of study treatment and death due to any cause, censored at the last contact date when the participant was alive.
| months | Treatment Period: Cohort A: Ponatinib 45 mg | Treatment Period: Cohort B: Ponatinib 30 mg | Treatment Period: Cohort C: Ponatinib 15 mg |
|---|---|---|---|
| Overall Survival (OS) | NA (NA to NA) | NA (NA to NA) | NA (NA to NA) |
Collected over From first dose up to 30 days after last dose of the study drug (up to approximately 9.8 years). Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Treatment Period: Cohort A: Ponatinib 45 mg | 19/94 (20.2%) | 38/94 (40.4%) | 93/94 (98.9%) |
| Treatment Period: Cohort B: Ponatinib 30 mg | 16/95 (16.8%) | 33/94 (35.1%) | 90/94 (95.7%) |
| Treatment Period: Cohort C: Ponatinib 15 mg | 14/94 (14.9%) | 39/94 (41.5%) | 90/94 (95.7%) |
| Close-out Period: Cohort A: Ponatinib 45 mg | 0/27 (0%) | 1/27 (3.7%) | 19/27 (70.4%) |
| Close-out Period: Cohort B: Ponatinib 30 mg | 0/17 (0%) | 3/17 (17.6%) | 16/17 (94.1%) |
| Close-out Period: Cohort C: Ponatinib 15 mg | 0/17 (0%) | 0/17 (0%) | 13/17 (76.5%) |
| Event | Treatment Period: Cohort A: Ponatinib 45 mg | Treatment Period: Cohort B: Ponatinib 30 mg | Treatment Period: Cohort C: Ponatinib 15 mg | Close-out Period: Cohort A: Ponatinib 45 mg | Close-out Period: Cohort B: Ponatinib 30 mg | Close-out Period: Cohort C: Ponatinib 15 mg |
|---|---|---|---|---|---|---|
| Cerebral ischaemiaNervous system disorders | 0/94 | 0/94 | 0/94 | 0/27 | 1/17 | 0/17 |
| Renal artery stenosisRenal and urinary disorders | 0/94 | 0/94 | 0/94 | 0/27 | 1/17 | 0/17 |
| Uterine polypReproductive system and breast disorders | 0/94 | 0/94 | 0/94 | 0/27 | 1/17 | 0/17 |
| ThrombocytopeniaBlood and lymphatic system disorders | 5/94 | 2/94 | 5/94 | 0/27 | 0/17 | 0/17 |
| PyrexiaGeneral disorders | 4/94 | 1/94 | 1/94 | 0/27 | 0/17 | 0/17 |
| Adenocarcinoma gastricNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/94 | 0/94 | 0/94 | 1/27 | 0/17 | 0/17 |
| Vertebrobasilar strokeNervous system disorders | 0/94 | 0/94 | 0/94 | 1/27 | 0/17 | 0/17 |
| AnaemiaBlood and lymphatic system disorders | 3/94 | 0/94 | 0/94 | 0/27 | 0/17 | 0/17 |
| Atrial fibrillationCardiac disorders | 2/94 | 3/94 | 1/94 | 0/27 | 0/17 | 0/17 |
| NeutropeniaBlood and lymphatic system disorders | 2/94 | 1/94 | 3/94 | 0/27 | 0/17 | 0/17 |
| Event | Treatment Period: Cohort A: Ponatinib 45 mg | Treatment Period: Cohort B: Ponatinib 30 mg | Treatment Period: Cohort C: Ponatinib 15 mg | Close-out Period: Cohort A: Ponatinib 45 mg | Close-out Period: Cohort B: Ponatinib 30 mg | Close-out Period: Cohort C: Ponatinib 15 mg |
|---|---|---|---|---|---|---|
| ThrombocytopeniaBlood and lymphatic system disorders | 40/94 | 36/94 | 36/94 | 4/27 | 0/17 | 0/17 |
| HypertensionVascular disorders | 31/94 | 38/94 | 27/94 | 4/27 | 4/17 | 1/17 |
| NeutropeniaBlood and lymphatic system disorders | 29/94 | 23/94 | 24/94 | 1/27 | 0/17 | 0/17 |
| Alanine aminotransferase increasedInvestigations | 25/94 | 9/94 | 21/94 | 2/27 | 0/17 | 3/17 |
| Lipase increasedInvestigations | 24/94 | 19/94 | 14/94 | 0/27 | 0/17 | 0/17 |
| ArthralgiaMusculoskeletal and connective tissue disorders | 12/94 | 23/94 | 15/94 | 0/27 | 0/17 | 0/17 |
| AnaemiaBlood and lymphatic system disorders | 22/94 | 19/94 | 17/94 | 1/27 | 0/17 | 0/17 |
| HeadacheNervous system disorders | 19/94 | 21/94 | 20/94 | 0/27 | 1/17 | 0/17 |
| HypertriglyceridaemiaMetabolism and nutrition disorders | 15/94 | 10/94 | 9/94 | 5/27 | 0/17 | 1/17 |
| PyrexiaGeneral disorders | 17/94 | 7/94 | 10/94 | 0/27 | 0/17 | 0/17 |
Safety Population included all participants who received at least one dose of study drug.
| Age, Continuous(years) | Treatment Period: Cohort A: Ponatinib 45 mg | Treatment Period: Cohort B: Ponatinib 30 mg | Treatment Period: Cohort C: Ponatinib 15 mg | Total |
|---|---|---|---|---|
| Mean | 47.7 ± 14.77 | 48.5 ± 12.90 | 48.8 ± 12.71 | 48.3 ± 13.45 |
| Sex: Female, Male(Participants) | Treatment Period: Cohort A: Ponatinib 45 mg | Treatment Period: Cohort B: Ponatinib 30 mg | Treatment Period: Cohort C: Ponatinib 15 mg | Total |
|---|---|---|---|---|
| Female | 44 | 56 | 41 | 141 |
| Male | 50 | 38 | 53 | 141 |
| Ethnicity (NIH/OMB)(Participants) | Treatment Period: Cohort A: Ponatinib 45 mg | Treatment Period: Cohort B: Ponatinib 30 mg | Treatment Period: Cohort C: Ponatinib 15 mg | Total |
|---|---|---|---|---|
| Hispanic or Latino | 22 | 26 | 20 | 68 |
| Not Hispanic or Latino | 70 | 67 | 72 | 209 |
| Unknown or Not Reported | 2 | 1 | 2 | 5 |
| Race/Ethnicity, Customized(Participants) | Treatment Period: Cohort A: Ponatinib 45 mg | Treatment Period: Cohort B: Ponatinib 30 mg | Treatment Period: Cohort C: Ponatinib 15 mg | Total |
|---|---|---|---|---|
| Race — Asian | 16 | 12 | 15 | 43 |
| Race — Black or African American | 1 | 2 | 3 | 6 |
| Race — White | 73 | 77 | 72 | 222 |
| Race — Unknown | 0 | 1 | 3 | 4 |
| Race — Other | 2 | 1 | 0 | 3 |
| Race — Missing | 2 | 1 | 1 | 4 |
| Region of Enrollment(Participants) | Treatment Period: Cohort A: Ponatinib 45 mg | Treatment Period: Cohort B: Ponatinib 30 mg | Treatment Period: Cohort C: Ponatinib 15 mg | Total |
|---|---|---|---|---|
| Argentina | 15 | 16 | 7 | 38 |
| Austria | 0 | 0 | 2 | 2 |
| Chile | 7 | 9 | 9 | 25 |
| Denmark | 0 | 0 | 1 | 1 |
| France | 2 | 1 | 2 | 5 |
| United Kingdom | 1 | 4 | 7 | 12 |
| Hong Kong | 1 | 3 | 2 | 6 |
| Italy | 0 | 3 | 0 | 3 |
| Japan | 5 | 2 | 4 | 11 |
| Poland | 4 | 6 | 5 | 15 |
| Russia | 38 | 31 | 38 | 107 |
| Singapore | 4 | 3 | 2 | 9 |
| Korea, Republic Of | 0 | 3 | 2 | 5 |
| Spain | 3 | 0 | 2 | 5 |
| Sweden | 0 | 2 | 1 | 3 |
| Taiwan, Province Of China | 4 | 1 | 2 | 7 |
| United States | 10 | 8 | 7 | 25 |
| Canada | 0 | 1 | 0 | 1 |
| Portugal | 0 | 1 | 1 | 2 |
| Weight(kg) | Treatment Period: Cohort A: Ponatinib 45 mg | Treatment Period: Cohort B: Ponatinib 30 mg | Treatment Period: Cohort C: Ponatinib 15 mg | Total |
|---|---|---|---|---|
| Mean | 78.14 ± 20.841 | 77.56 ± 18.375 | 76.71 ± 17.434 | 77.47 ± 18.879 |
| Height(meter) | Treatment Period: Cohort A: Ponatinib 45 mg | Treatment Period: Cohort B: Ponatinib 30 mg | Treatment Period: Cohort C: Ponatinib 15 mg | Total |
|---|---|---|---|---|
| Mean | 1.68 ± 0.104 | 1.68 ± 0.098 | 1.68 ± 0.090 | 1.68 ± 0.097 |
| Eastern Cooperative Oncology Group (ECOG) Performance Status (PS) Score(Participants) | Treatment Period: Cohort A: Ponatinib 45 mg | Treatment Period: Cohort B: Ponatinib 30 mg | Treatment Period: Cohort C: Ponatinib 15 mg | Total |
|---|---|---|---|---|
| Score= 0 | 74 | 73 | 72 | 219 |
| Score= 1 | 19 | 20 | 22 | 61 |
| Score= 2 | 1 | 1 | 0 | 2 |
5 further baseline measures are reported on the registry.
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — Takeda provides access to the de-identified individual participant data (IPD) for eligible studies to aid qualified researchers in addressing legitimate scientific objectives (Takeda's data sharing commitment is available on https://clinicaltrials.takeda.com/takedas-commitment?commitment=5). These IPDs will be provided in a secure research environment following approval of a data sharing request, and under the terms of a data sharing agreement.
Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report
Access criteria: IPD from eligible studies will be shared with qualified researchers according to the criteria and process described on https://vivli.org/ourmember/takeda/. For approved requests, the researchers will be provided access to anonymized data (to respect patient privacy in line with applicable laws and regulations) and with information necessary to address the research objectives under the terms of a data sharing agreement.
Data sharing details ↗ · vivli.org
Ran from Jul 2015 to primary completion in Apr 2020, 57 months.
Results were first posted in Jun 2021, 1 year 1 month after primary completion.
Of 49 phase 2 interventional studies under Leukemia, Myeloid, Chronic-Phase, half reached primary completion within 70 months of starting (the median), counting those still running; a quarter within 43 and three quarters within 132. This study's 57 months is below that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Mar 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Ponatinib
Leukemia, Myeloid, Chronic-Phase →